DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares
by Doug Wharley · The Cerbat GemDexCom, Inc. (NASDAQ:DXCM – Get Free Report) EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $63.04, for a total value of $107,168.00. Following the sale, the executive vice president owned 111,204 shares in the company, valued at approximately $7,010,300.16. This trade represents a 1.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Jon Brown also recently made the following trade(s):
- On Monday, March 16th, Michael Jon Brown sold 1,700 shares of DexCom stock. The stock was sold at an average price of $64.85, for a total value of $110,245.00.
DexCom Trading Down 0.5%
DexCom stock traded down $0.31 during midday trading on Thursday, reaching $61.23. The stock had a trading volume of 5,745,421 shares, compared to its average volume of 3,723,623. The stock’s 50-day simple moving average is $67.48 and its 200 day simple moving average is $66.75. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The stock has a market capitalization of $23.56 billion, a PE ratio of 29.16, a price-to-earnings-growth ratio of 1.20 and a beta of 1.55.
DexCom (NASDAQ:DXCM – Get Free Report) last released its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.The firm’s revenue was up 13.1% compared to the same quarter last year. During the same period last year, the company posted $0.45 earnings per share. Analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.
Institutional Trading of DexCom
Several hedge funds have recently modified their holdings of DXCM. Norges Bank bought a new position in DexCom in the fourth quarter valued at approximately $483,356,000. AQR Capital Management LLC grew its position in shares of DexCom by 597.8% in the 4th quarter. AQR Capital Management LLC now owns 3,102,789 shares of the medical device company’s stock valued at $205,932,000 after acquiring an additional 2,658,158 shares during the period. Holocene Advisors LP bought a new position in shares of DexCom in the 3rd quarter valued at about $163,964,000. CIBC Private Wealth Group LLC boosted its holdings in shares of DexCom by 374.3% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,907,801 shares of the medical device company’s stock worth $195,666,000 after buying an additional 2,294,709 shares during the period. Finally, Employees Provident Fund Board acquired a new stake in DexCom in the 4th quarter worth about $145,352,000. 97.75% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
DXCM has been the topic of several research reports. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Citigroup boosted their price target on shares of DexCom from $77.00 to $84.00 and gave the company a “buy” rating in a report on Wednesday, March 11th. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Finally, Barclays restated an “underweight” rating and set a $72.00 price target (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $86.50.
Read Our Latest Analysis on DexCom
About DexCom
DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.
Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.